Discontinuation report EVUSHELD
Report ID | 224094 |
Drug Identification Number | 02526271 |
Brand name | EVUSHELD |
Common or Proper name | CILGAVIMAB TIXAGEVIMAB SOLUTION |
Company Name | ASTRAZENECA CANADA INC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | |
Strength(s) | 150MG 150MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAMUSCULAR |
Packaging size | 2 single dose vials |
ATC code | J06BD |
ATC description | |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | |
Actual discontinuation date | 2024-03-27 |
Remaining supply date | 2023-01-09 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Company contact information | Please contact AstraZeneca Canada Medical Information for any specific questions at 1-800-668-6000 (EN) or 1-800-461-3787 (FR) or by email: medinfo.canada@astrazeneca.com. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2024-04-04 | French | Compare |
v5 | 2024-04-04 | English | Compare |
v4 | 2024-04-02 | French | Compare |
v3 | 2024-04-02 | English | Compare |
v2 | 2024-04-02 | French | Compare |
v1 | 2024-04-02 | English | Compare |
Showing 1 to 6 of 6